Blood Res.  2023 Dec;58(4):237-240. 10.5045/br.2023.2023185.

Successful recovery of poor graft function by administration of romiplostim in a multiple myeloma case with poor graft function following autologous stem cell transplantation

• Yim J
• Park SS
• Lee JM
• Yoon JH
• Kim HJ
• Min CK

• KMID: 2550206
• DOI: http://doi.org/10.5045/br.2023.2023185

Figure

• 

  Fig. 1 Images of bone marrow at different time points: before autologous stem cell transplantation (ASCT, upper row: A–D); at 282 days after ASCT, when the patient was diagnosed with poor graft function (middle row: E–H); and at 138 weeks after initiation of romiplostim, demonstrating stringent complete response of multiple myeloma with no evidence of fibrosis or dyspoiesis (lower row: I–L). The first column (A, E, and I) presents bone marrow aspiration, magnified ×100; the second column (B, F, and J) illustrates bone marrow biopsy, magnified ×100; the third column (C, G, and K) shows kappa staining, magnified as ×40 to ×100; the fourth column (D, H, and L) shows lambda staining magnified ×40 to ×100.

• 

  Fig. 2 Dynamics of platelet count (unit, ×109/L) and absolute neutrophil count (unit, ×109/L) following aut-ologous hematopoietic stem cell transplant and the response to romiplostim.

Reference

1. Jung SH, Jo JC, Song GY, et al. 2020; Frontline therapy for newly diagnosed patients with multiple myeloma. Blood Res. 55(S1):S37–42. DOI: 10.5045/br.2020.S007. PMID: 32719175. PMCID: PMC7386893.

2. Valcárcel D, Sureda A. Carreras E, Dufour C, Mohty M, Kröger N, editors. 2019. Graft failure. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. 7th ed. Springer;Cham: p. 307–13. DOI: 10.1007/978-3-030-02278-5_41. PMID: 32091792.

3. McGuirk JP, Metheny L 3rd, Pineiro L, et al. 2023; Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: a phase I study. Bone Marrow Transplant. 58:1189–96. DOI: 10.1038/s41409-023-02068-3. PMID: 37553467. PMCID: PMC10622312.

4. Hequet O, Salles G, Ketterer N, et al. 2003; Autoimmune thrombocytopenic purpura after autologous stem cell transplantation. Bone Marrow Transplant. 32:89–95. DOI: 10.1038/sj.bmt.1704073. PMID: 12815483.

5. Bortolotti M, Pettine L, Zaninoni A, Croci GA, Barcellini W, Fattizzo B. 2022; Efficacy and immunomodulating properties of eltrombopag in aplastic anemia following autologous stem cell transplant: case report and review of the literature. Pharmaceuticals (Basel). 15:419. DOI: 10.3390/ph15040419. PMID: 35455416. PMCID: PMC9032708. PMID: 463984b55e7443c0aee55df8351942e9.

6. Young NS. 2018; Aplastic anemia. N Engl J Med. 379:1643–56. DOI: 10.1056/NEJMra1413485. PMID: 30354958. PMCID: PMC6467577.

7. Jang JH, Tomiyama Y, Miyazaki K, et al. 2021; Efficacy and safety of romiplostim in refractory aplastic anaemia: a phase II/III, multicentre, open-label study. Br J Haematol. 192:190–9. DOI: 10.1111/bjh.17190. PMID: 33152120. PMCID: PMC7821109.

8. Song GY, Jung SH, Kim JS, et al. 2022; Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study). Front Oncol. 12:959949. DOI: 10.3389/fonc.2022.959949. PMID: 36110935. PMCID: PMC9468269. PMID: 1bd23d127d07481d97dbc28a45ba6614.

9. Park YH, Kim DY, Kim S, et al. 2022; Management of immune thrombocytopenia: 2022 update of Korean experts recommendations. Blood Res. 57:20–8. DOI: 10.5045/br.2022.2022043. PMID: 35342042. PMCID: PMC8958378.

10. Lutfi F, Skelton WP, Rosenau E, et al. 2017; Poor graft function following autologous stem cell transplant (ASCT): a retrospective analysis over two decades at a transplant center. Blood. 130 Suppl 1:4529. DOI: 10.26226/morressier.5b3b802db1b87b000eced956.

11. Prabahran A, Koldej R, Chee L, Ritchie D. 2022; Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation. Blood Adv. 6:1947–59. DOI: 10.1182/bloodadvances.2021004537. PMID: 34492685. PMCID: PMC8941468.

12. González-Porras JR, Mingot-Castellano ME, Andrade MM, et al. 2015; Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol. 169:111–6. DOI: 10.1111/bjh.13266. PMID: 25521630.

13. Ise M, Iizuka H, Kamoda Y, Hirao M, Kida M, Usuki K. 2020; Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study. Int J Hematol. 112:787–94. DOI: 10.1007/s12185-020-02971-1. PMID: 32876852.

14. Ahn HJ, Byun JM, Kim I, et al. 2022; Eltrombopag for post-transplant poor graft function in East Asian patients. J Korean Med Sci. 37:e48. DOI: 10.3346/jkms.2022.37.e48. PMID: 35166084. PMCID: PMC8845101.